Literature DB >> 18463966

Graft-versus-tumor effect after reduced-intensity allogeneic hematopoietic stem cell transplantation in a patient with advanced colon cancer.

Satoshi Hashino1, Sumiko Kobayashi, Mutsumi Takahata, Masahiro Onozawa, Masao Nakagawa, Takahito Kawamura, Fumie Fujisawa, Koh Izumiyama, Kaoru Kahata, Takeshi Kondo, Masahiro Asaka.   

Abstract

A 27-year-old man with advanced colon cancer that was resistant to conventional chemoradiotherapies was treated with reduced-intensity allogeneic peripheral blood stem cell transplantation (PBSCT). After obtaining complete donor-type chimerism, there was an apparent graft-versus-tumor effect accompanied by severe hepatic graft-versus-host disease (GVHD) showing hyperbilirubinemia, resulting in a stable disease condition that lasted for 18 months, which had not been seen previously in his previous disease history. The antitumor effect observed in this patient was insufficient for the patient to achieve complete remission, because the disease was at an already widespread and treatment-resistant stage. He finally died of hepatic failure due to extensive liver GVHD 65 months after the diagnosis of the advanced colon cancer and 29 months after the allogeneic PBSCT. Prospective studies are necessary to achieve better clinical results in patients with advanced colon cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18463966     DOI: 10.1007/s10147-007-0716-4

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  18 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Urgent need for a validated tumor response evaluation system for use in immunotherapy.

Authors:  A Hori; M Kami; S-W Kim; N Murashige; M Sakiyama; R Kojima; T Hamaki; A Makimoto; S Miyakoshi; S Masuo; S Taniguchi; H Kunitoh; Y Takaue
Journal:  Bone Marrow Transplant       Date:  2004-01       Impact factor: 5.483

3.  Reduced-intensity allogeneic hematopoietic stem-cell transplantation as an immunotherapy for metastatic colorectal cancer.

Authors:  Rie Kojima; Masahiro Kami; Akiko Hori; Naoko Murashige; Mutsuko Ohnishi; Sung-Won Kim; Tamae Hamaki; Yukiko Kishi; Yutaka Tsutsumi; Nobuo Masauzi; Yuji Heike; Shin-Ichiro Mori; Kazuhiko Kobayashi; Shigeru Masuo; Ryuji Tanosaki; Yoichi Takaue
Journal:  Transplantation       Date:  2004-12-27       Impact factor: 4.939

4.  Guidelines for the use of carcinoembryonic antigen in colorectal cancer.

Authors:  C D Atkins
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

Review 5.  New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.

Authors:  K D Holen; L B Saltz
Journal:  Lancet Oncol       Date:  2001-05       Impact factor: 41.316

6.  Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma.

Authors:  P Hentschke; L Barkholt; M Uzunel; J Mattsson; P Wersäll; P Pisa; J Martola; N Albiin; A Wernerson; M Söderberg; M Remberger; A Thörne; O Ringdén
Journal:  Bone Marrow Transplant       Date:  2003-02       Impact factor: 5.483

7.  Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes.

Authors:  J H Falkenburg; A R Wafelman; P Joosten; W M Smit; C A van Bergen; R Bongaerts; E Lurvink; M van der Hoorn; P Kluck; J E Landegent; H C Kluin-Nelemans; W E Fibbe; R Willemze
Journal:  Blood       Date:  1999-08-15       Impact factor: 22.113

8.  Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer.

Authors:  Marco Bregni; Anna Dodero; Jacopo Peccatori; Alessandra Pescarollo; Massimo Bernardi; Isabella Sassi; Claudia Voena; Alberto Zaniboni; Claudio Bordignon; Paolo Corradini
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

Authors:  H J Kolb; A Schattenberg; J M Goldman; B Hertenstein; N Jacobsen; W Arcese; P Ljungman; A Ferrant; L Verdonck; D Niederwieser; F van Rhee; J Mittermueller; T de Witte; E Holler; H Ansari
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

View more
  3 in total

1.  Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives.

Authors:  Timothy J Zumwalt; Ajay Goel
Journal:  Curr Colorectal Cancer Rep       Date:  2015-06-29

2.  Cyclodextrin-PEI-Tat Polymer as a Vector for Plasmid DNA Delivery to Placenta Mesenchymal Stem Cells.

Authors:  Wing-Fu Lai; Gu-Ping Tang; Xin Wang; Guo Li; Hong Yao; Zan Shen; Gang Lu; Wai Sang Poon; Hsiang-Fu Kung; Marie C M Lin
Journal:  Bionanoscience       Date:  2011-06-18

Review 3.  Stem cells in clinical practice: applications and warnings.

Authors:  Daniele Lodi; Tommaso Iannitti; Beniamino Palmieri
Journal:  J Exp Clin Cancer Res       Date:  2011-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.